News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
527,358 Results
Type
Article (17032)
Company Profile (162)
Press Release (510163)
Multimedia
Podcasts (96)
Webinars (15)
Section
Business (181069)
Career Advice (796)
Deals (28604)
Drug Delivery (110)
Drug Development (59134)
Employer Resources (52)
FDA (10832)
Job Trends (9659)
News (260163)
Policy (20544)
Tag
2027 BioCapital Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (2)
2027 Genetown Standard (5)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (630)
Accelerated approval (36)
ADA (27)
Adcomms (22)
Allergies (116)
Alliances (36669)
ALS (137)
Alzheimer's disease (1213)
Antibody-drug conjugate (ADC) (399)
Approvals (11382)
Artificial intelligence (511)
ASCO (203)
Autoimmune disease (280)
Automation (38)
Bankruptcy (303)
Belgium (5)
Best Places to Work (7353)
BIO (53)
Biologics (17)
BIOSECURE Act (10)
Biosimilars (183)
BioSpace Insights (72)
Biotechnology (99)
Bispecific (5)
Bladder cancer (162)
Brain cancer (41)
Breast cancer (581)
Cancer (4567)
Cardiovascular disease (366)
Career advice (664)
Career pathing (30)
CAR-T (230)
CDC (14)
CDMO (99)
Celiac Disease (2)
Cell-line development (1)
Cell therapy (619)
Cervical cancer (38)
Clinical research (53306)
Collaboration (1662)
Commercialization (14)
Company closure (3)
Compensation (1590)
Complete response letters (68)
COVID-19 (1070)
CRISPR (74)
C-suite (1027)
Cystic fibrosis (92)
Data (6502)
Decentralized trials (1)
Denatured (18)
Depression (138)
Dermatology (103)
Diabetes (473)
Diagnostics (4490)
Digital health (47)
Diversity (8)
Diversity, equity & inclusion (13)
Drug discovery (259)
Drug pricing (173)
Drug shortages (26)
Duchenne muscular dystrophy (219)
Earnings (76856)
Editorial (48)
Employer branding (7)
Employer resources (58)
Events (93380)
Executive appointments (856)
FDA (13895)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (20)
Frontotemporal dementia (27)
Funding (1235)
Gene editing (156)
Generative AI (47)
Gene therapy (456)
GLP-1 (723)
Government (1659)
Grass and pollen (3)
Guidances (302)
Healthcare (10137)
Hematology (108)
HIV (71)
Huntington's disease (37)
Idiopathic pulmonary fibrosis (4)
IgA nephropathy (87)
Immunology and inflammation (275)
Immuno-oncology (96)
Indications (180)
Infectious disease (1333)
Inflammatory bowel disease (156)
Inflation Reduction Act (8)
Influenza (94)
Intellectual property (279)
Interviews (111)
IPO (13305)
IRA (42)
Job creations (2518)
Job search strategy (580)
JPM (40)
Kidney cancer (19)
Kidney disease (57)
Labor market (85)
Layoffs (286)
Leadership (33)
Legal (5815)
Licensing (32)
Liver cancer (61)
Longevity (25)
Lung cancer (658)
Lung diease (12)
Lymphoma (328)
Machine learning (38)
Management (24)
Manufacturing (925)
Marketing (10)
MASH (159)
Medical affairs (2)
Medical device (8880)
Medtech (9047)
Mergers & acquisitions (16426)
Metabolic disorders (1265)
mRNA (128)
Multiple sclerosis (140)
NASH (12)
Netherlands (4)
Neurodegenerative disease (322)
Neuropsychiatric disorders (86)
Neuroscience (2411)
Neurotech (1)
NextGen: Class of 2026 (3545)
Non-profit (945)
Now hiring (58)
Obesity (621)
Opinion (177)
Ovarian cancer (181)
Pain (224)
Pancreatic cancer (246)
Parkinson's disease (261)
Partnered (22)
Patents (590)
Patient advocacy (1)
Patient recruitment (587)
Patient selection (16)
Peanut (37)
People (45468)
Peptides (5)
Pharmaceutical (39)
Pharmacy benefit managers (29)
Phase 1 (16916)
Phase 2 (23851)
Phase 3 (16747)
Pipeline (8818)
Policy (210)
Postmarket research (1686)
Preclinical (7009)
Press Release (35)
Prostate cancer (227)
Psychedelics (39)
Radiopharmaceuticals (255)
Rare diseases (834)
Real estate (3624)
Recruiting (27)
Regenerative medicine (7)
Regulatory (17233)
Reports (36)
Research institute (743)
Resumes & cover letters (135)
Rett syndrome (44)
RNA editing (17)
RSV (74)
Schizophrenia (163)
Series A (216)
Series B (158)
Service/supplier (7)
Sickle cell disease (76)
Special edition (23)
Spinal muscular atrophy (111)
Sponsored (14)
Startups (2471)
Stomach cancer (12)
Substance use disorders (18)
Supply chain (94)
Tariffs (93)
The Weekly (76)
Vaccines (513)
Venture capital (106)
Weight loss (407)
Wet AMD (1)
Women's health (107)
Worklife (10)
Date
Last 7 days (401)
Last 30 days (1542)
Last 365 days (21783)
2026 (16417)
2025 (21874)
2024 (25577)
2023 (28965)
2022 (37592)
2021 (39931)
2020 (36055)
2019 (26018)
2018 (19682)
2017 (21693)
2016 (20591)
2015 (26371)
2014 (23139)
2013 (19450)
2012 (21513)
2011 (21769)
2010 (21284)
Location
Africa (379)
Alabama (82)
Alaska (2)
Arizona (327)
Arkansas (12)
Asia (23716)
Australia (2724)
California (12878)
Canada (3447)
China (862)
Colorado (538)
Connecticut (479)
Delaware (255)
Europe (40729)
Florida (1994)
Georgia (400)
Hawaii (3)
Idaho (46)
Illinois (792)
India (92)
Indiana (376)
Iowa (18)
Japan (547)
Kansas (107)
Kentucky (35)
Louisiana (29)
Maine (27)
Maryland (1346)
Massachusetts (8619)
Michigan (324)
Minnesota (589)
Mississippi (5)
Missouri (85)
Montana (20)
Nebraska (14)
Nevada (127)
New Hampshire (62)
New Jersey (3013)
New Mexico (25)
New York (3096)
North Carolina (1430)
North Dakota (4)
Northern California (6458)
Ohio (345)
Oklahoma (15)
Oregon (22)
Pennsylvania (2417)
Puerto Rico (32)
Rhode Island (33)
South America (569)
South Carolina (78)
South Dakota (1)
Southern California (5356)
Tennessee (137)
Texas (2084)
United States (42419)
Utah (391)
Vermont (1)
Virginia (177)
Washington D.C. (52)
Washington State (1007)
West Virginia (2)
Wisconsin (86)
Wyoming (2)
527,358 Results for "ascendis pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Legal
Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis
Biomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter company’s recently approved achondroplasia drug Yuviwel, in exchange for 18–20% royalties on net sales.
August 31, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
Ascendis Pharma Reports Second Quarter 2026 Financial Results
August 13, 2026
·
22 min read
Press Releases
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
September 8, 2026
·
4 min read
Press Releases
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
August 31, 2026
·
4 min read
Pipeline
Ascendis retreats to rare endocrinology wheelhouse as cancer plans falter
Before discontinuing the asset, Ascendis Pharma was studying onvapegleukin alfa in advanced or metastatic solid tumors, demonstrating a three- to four-month overall survival advantage over historical controls.
May 8, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Ascendis Announces Planned $400 Million Share Repurchase Program
September 14, 2026
·
4 min read
Press Releases
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
September 14, 2026
·
5 min read
Press Releases
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
September 7, 2026
·
6 min read
Press Releases
Ascendis Pharma Reports First Quarter 2026 Financial Results
May 7, 2026
·
22 min read
Mergers & acquisitions
Revolution, Ascendis Named Top Buyout Targets as Industry Awaits The Big One
Prime biotech buyout targets such as Revolution Medicines and Ascendis Pharma have recently found themselves in the middle of acquisition rumors—though no deals have panned out so far.
March 19, 2026
·
2 min read
·
Tristan Manalac
1 of 52,736
Next